KUR 113
Alternative Names: Fibrin-PTH; I-040202; KUR-113; TGplPTH 134Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Kuros Biosurgery
- Developer Kuros Biosciences; Kuros Biosurgery
- Class Blood proteins; Peptide hormones
- Mechanism of Action Parathyroid hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Fracture; Intervertebral disc degeneration
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Intervertebral-disc-degeneration in Switzerland
- 27 Dec 2023 Interim efficacy and adverse events data from a phase II STRUCTURE trial in Intervertebral disc degeneration released by Kuros Biosciences
- 18 Jul 2023 Kuros Biosciences completes enrolment in its phase-II STRUCTURE trial in Intervertebral disc degeneration in the US